Search Results - Frank Bruchertseifer

Therapeutic Performance Evaluation of ²¹³Bi-Labelled Aminopeptidase N (APN/CD13)-Affine NGR-Motif ([²¹³Bi]Bi-DOTAGA-cKNGRE) in Experimental Tumour Model: A Tr... by Zita Képes, Viktória Arató, Judit P. Szabó, Barbara Gyuricza, Dániel Szücs, István Hajdu, Anikó Fekete, Frank Bruchertseifer, Dezső Szikra, György Trencsényi

Connect to this object online.

First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs by Maryana Handula, Savanne Beekman, Mark Konijnenberg, Debra Stuurman, Corrina de Ridder, Frank Bruchertseifer, Alfred Morgenstern, Antonia Denkova, Erik de Blois, Yann Seimbille

Connect to this object online.

Optimizing labelling conditions of 213Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy by Ho Sze Chan, Erik de Blois, Mark W. Konijnenberg, Alfred Morgenstern, Frank Bruchertseifer, Jeffrey P. Norenberg, Fred J. Verzijlbergen, Marion de Jong, Wouter A. P. Breeman

Connect to this object online.

Development of [²²⁵Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC by Eline L. Hooijman, Yozlem Chalashkan, Sui Wai Ling, Figen F. Kahyargil, Marcel Segbers, Frank Bruchertseifer, Alfred Morgenstern, Yann Seimbille, Stijn L. W. Koolen, Tessa Brabander, Erik de Blois

Connect to this object online.

Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model by Robin I. J. Merkx, Mark Rijpkema, Gerben M. Franssen, Annemarie Kip, Bart Smeets, Alfred Morgenstern, Frank Bruchertseifer, Eddie Yan, Michael P. Wheatcroft, Egbert Oosterwijk, Peter F. A. Mulders, Sandra Heskamp

Connect to this object online.